<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; BMS</title>
	<atom:link href="http://www.tapanray.in/tag/bms/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unilateral American Action on Agreed Bilateral Issues: Would India Remain Unfazed?</title>
		<link>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed</link>
		<comments>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/#comments</comments>
		<pubDate>Mon, 20 Oct 2014 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bilateral]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[cold]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[doctors without borders]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[feet]]></category>
		<category><![CDATA[healthBig]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[President Obama]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[sprycel]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Unfazed]]></category>
		<category><![CDATA[Unilateral]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6128</guid>
		<description><![CDATA[I discussed in one of my earlier blog posts titled “Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?” of October 6, 2014 that on April 30, 2014, the United States in its report on annual review &#8230; <a href="http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An El Dorado&#8230;But Not Without Responsible Pricing:The Cancer Segment in India</title>
		<link>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area</link>
		<comments>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[British]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[oral]]></category>
		<category><![CDATA[ovarian]]></category>
		<category><![CDATA[ovary]]></category>
		<category><![CDATA[pancreatic]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[pots]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1493</guid>
		<description><![CDATA[The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the &#8230; <a href="http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Government Ups the Ante for More Compulsory Licenses in India</title>
		<link>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=government-ups-the-ante-for-more-compulsory-licenses-in-india</link>
		<comments>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/#comments</comments>
		<pubDate>Mon, 21 Jan 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[deficiencies]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[nurses]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[skewed]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[third]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[uncertainty]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1442</guid>
		<description><![CDATA[On January 12, 2013, one of the leading dailies of India first reported that in a move that is intended to benefit thousands of cancer patients, Indian Government has started the process of issuing Compulsory Licenses (CL) for three commonly &#8230; <a href="http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
